MS4A1 and myeloid sarcoma: As anti-CD20 therapy in MS clearly affects peripheral B cells as well as T cells, we comprehensively analyzed the adaptive immune-receptor repertoire of both compartments before and six months after the start of ocrelizumab therapy by genomic DNA (gDNA) bulk sequencing in synopsis with flow cytometry data and CSF and peripheral blood single-cell RNA sequencing (scRNA-seq) data, to evaluate how ocrelizumab therapy modulates the B cell receptor (BCR) and T cell receptor (TCR) repertoire with special regard to therapy-resistant phenotypes.